You are here
Stomach cancerThis trial is comparing a new drug called MK-2870 with standard chemotherapy for cancer that has spread into surrounding tissues or to another part of the body.
This trial is looking at the targeted drug trastuzumab deruxtecan after surgery for people with oesophageal, stomach or gastro oesophageal junction cancer.
This study is looking at the products people buy to help with vague symptoms that could be cancer.
This trial is comparing standard follow up with more frequent follow up visits and scans.
This trial is looking at the best dose of HTL0039732 for solid tumours that have spread to another part of the body.
There are around 6,600 new stomach cancer cases in the UK every year, that's 18 every day (2017-2019).
Stomach cancer is the 18th most common cancer in the UK, accounting for 2% of all new cancer cases (2017-2019).
In females in the UK, stomach cancer is the 19th most common cancer, with around 2,300 new cases every year (2017-2019).
In males in the UK, stomach cancer is the 14th most common cancer, with around 4,200 new cases every year (2017-2019).
This trial is looking at a new drug called datopotamab deruxtecan (Dato Dxd) on its own, or with other treatments, for some solid cancers.
This study is taking blood and tissue samples from people with oesophageal cancer and stomach cancer.
This study is looking at a drug called INCB106385 by itself or with another immunotherapy called retifanlimab (INCMGA00012) for some advanced solid cancers.
This trial is looking at trastuzumab deruxtecan for stomach cancer that has spread into the nearby tissue or to another part of the body.
